Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Shenyin Zhu"'
Autor:
Xiaowen Zhong, Chenyang Li, Guangzong Zhao, Mengmeng Li, Shuning Chen, Yang Cao, Qi Wang, Jiangchuan Sun, Shenyin Zhu, Shufang Chang
Publikováno v:
Journal of Nanobiotechnology, Vol 20, Iss 1, Pp 1-20 (2022)
Abstract The hypoimmunogenicity of tumors is one of the main bottlenecks of cancer immunotherapy. Enhancing tumor immunogenicity can improve the efficacy of tumor immunotherapy by increasing antigen exposure and presentation, and establishing an infl
Externí odkaz:
https://doaj.org/article/e9f5057a2428463481a2c7c547f155aa
Autor:
Shuning Chen, Yujiao Liu, Shenyin Zhu, Chunyan Chen, Wan Xie, Linlin Xiao, Yi Zhu, Lan Hao, Zhigang Wang, Jiangchuan Sun, Shufang Chang
Publikováno v:
Drug Delivery, Vol 25, Iss 1, Pp 1683-1693 (2018)
Chemotherapy and photo-sonodynamic therapy (PSDT) can be combined through drug delivery nano-platforms to enhance the anti-tumor efficacy, however, which is limited by hypoxia in tumor, thereby causing chemotherapy resistance. Perfluoropentane (PFP)
Externí odkaz:
https://doaj.org/article/f82bdc2f5cb54a288ec880b11dacff04
Publikováno v:
British journal of clinical pharmacologyREFERENCES.
To identify and characterize ocular adverse events (oAEs) that are significantly associated with proprotein convertase subtilisin-like/kexin type 9 (PCSK9) inhibitors using the US Food and Drug Administration Adverse Event Reporting System (FAERS).We
Publikováno v:
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Xuemei Li,1,2 Qingfeng Cheng,3 Zhipeng Du,3 Shenyin Zhu,2 Chao Cheng4 1Department of Pharmacy, Chongqing Health Center for Women and Children, Chongqing, People’s Republic of China; 2Department of Pharmacy, First Affiliated Hospital of Chongqing Me
Publikováno v:
Molecular pharmaceutics. 19(7)
Rheumatoid arthritis (RA), a common chronic inflammatory joint disease with features of synovitis and pannus formation, may lead to irreparable joint damage and disability. Methotrexate (MTX) is known as the cornerstone of therapy for RA. However, th
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 45:856-862
What is known and objective Imatinib mesylate (IM) is the first-line therapy for unresectable or metastatic gastrointestinal stromal tumours (GISTs). Here, we report a case of successful progressive dose optimization by therapeutic drug monitoring (T
Publikováno v:
Journal of Diabetes and its Complications. 36:108352
To update the meta-analysis of the metabolic effects of a dual sodium-glucose co-transpoter-1/2 inhibitor, sotagliflozin, on blood pressure (BP) and body weight in people with diabetes.An electronic search up to March 8, 2022, were conducted to deter
Autor:
Zhigang Wang, Shuning Chen, Jiangchuan Sun, Shenyin Zhu, Shufang Chang, Chunyan Chen, Yujiao Liu
Publikováno v:
International Journal of Nanomedicine. 14:753-769
Purpose Nanomedicine has emerged as a novel therapeutic modality for cancer treatment and diagnosis. Lipid-polymer hybrid nanoparticles (LPHNPs) are core-shell nanoparticle (NP) structures comprising polymer cores and lipid shells, which exhibit comp
Publikováno v:
Journal of clinical pharmacy and therapeuticsREFERENCES. 46(4)
What is known and objective Previous studies based on small-sample clinical data proved that short-term use of hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitors increased haemoglobin levels in anaemic patients with chronic kidney disea
Autor:
Shuning Chen, Jiao Zheng, Jiangchuan Sun, Shufang Chang, Lan Hao, Jia Chen, Zhigang Wang, Yujiao Liu, Shenyin Zhu
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society. 332
Immunotherapy by stimulating the host immune system has been a promising therapeutic strategy for advanced ovarian cancer. Here we describe a treatment strategy that combines chemotherapy and photo-sonodynamic therapy (PSDT) to induce systemic antitu